Vanguard Global Advisers
JANX icon

Vanguard Global Advisers’s Janux Therapeutics JANX Stock Holding History

Vanguard Global Advisers’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Hold
19,779
– – ﹤0.01% 2326
2026
Q1 		$275K Buy
+19,779
New +$271K ﹤0.01% 2285

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Global Advisers's JANX Position: Q2 2026 in Review

Vanguard Global Advisers held its Janux Therapeutics (JANX) position steady in Q2 2026 at 19,779 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Vanguard Global Advisers first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Vanguard Global Advisers held 19,779 shares of Janux Therapeutics worth $304K as of Q2 2026.
  • Vanguard Global Advisers left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2326 holding.
  • Vanguard Global Advisers first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.